Characterization of Ebastine, Hydroxyebastine, and Carebastine Metabolism by Human Liver Microsomes and Expressed Cytochrome P450 Enzymes: Major Roles for CYP2J2 and CYP3A
Open Access
- 8 August 2006
- journal article
- Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) in Drug Metabolism and Disposition
- Vol. 34 (11), 1793-1797
- https://doi.org/10.1124/dmd.106.010488
Abstract
Ebastine undergoes extensive metabolism to form desalkylebastine and hydroxyebastine. Hydroxyebastine is subsequently metabolized to carebastine. Although CYP3A4 and CYP2J2 have been implicated in ebastine N-dealkylation and hydroxylation, the enzyme catalyzing the subsequent metabolic steps (conversion of hydroxyebastine to desalkylebastine and carebastine) have not been identified. Therefore, we used human liver microsomes (HLMs) and expressed cytochromes P450 (P450s) to characterize the metabolism of ebastine and that of its metabolites, hydroxyebastine and carebastine. In HLMs, ebastine was metabolized to desalkyl-, hydroxy-, and carebastine; hydroxyebastine to desalkyl- and carebastine; and carebastine to desalkylebastine. Of the 11 cDNA-expressed P450s, CYP3A4 was the main enzyme catalyzing the N-dealkylation of ebastine, hydroxyebastine, and carebastine to desalkylebastine [intrinsic clearance (CLint) = 0.44, 1.05, and 0.16 μl/min/pmol P450, respectively]. Ebastine and hydroxyebastine were also dealkylated to desalkylebastine to some extent by CYP3A5. Ebastine hydroxylation to hydroxyebastine is mainly mediated by CYP2J2 (0.45 μl/min/pmol P450; 22.5- and 7.5-fold higher than that for CYP3A4 and CYP3A5, respectively), whereas CYP2J2 and CYP3A4 contributed to the formation of carebastine from hydroxyebastine. These findings were supported by chemical inhibition and kinetic analysis studies in human liver microsomes. The CLint of hydroxyebastine was much higher than that of ebastine and carebastine, and carebastine was metabolically more stable than ebastine and hydroxyebastine. In conclusion, our data for the first time, to our knowledge, suggest that both CYP2J2 and CYP3A play important roles in ebastine sequential metabolism: dealkylation of ebastine and its metabolites is mainly catalyzed by CYP3A4, whereas the hydroxylation reactions are preferentially catalyzed by CYP2J2. The present data will be very useful to understand the pharmacokinetics and drug interaction of ebastine in vivo.Keywords
This publication has 10 references indexed in Scilit:
- Co‐administration of ketoconazole with H1‐antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effectsBritish Journal of Clinical Pharmacology, 2005
- Simultaneous determination of ebastine and its three metabolites in plasma using liquid chromatography-tandem mass spectrometryJournal of Chromatography B, 2004
- Pharmacokinetics and Safety of Ebastine in Patients with Impaired Hepatic Function Compared with Healthy VolunteersClinical Pharmacokinetics, 2004
- In vitro inhibition of human small intestinal and liver microsomal astemizole O -demethylation: different contribution of CYP2J2 in the small intestine and liverXenobiotica, 2003
- The Cytochrome P450 2B6 (CYP2B6) Is the Main Catalyst of Efavirenz Primary and Secondary Metabolism: Implication for HIV/AIDS Therapy and Utility of Efavirenz as a Substrate Marker of CYP2B6 Catalytic ActivityThe Journal of pharmacology and experimental therapeutics, 2003
- Inhibitory Effects of Tricyclic Antidepressants (TCAs) on Human Cytochrome P450 Enzymes in Vitro: Mechanism of Drug Interaction between TCAs and PhenytoinDrug Metabolism and Disposition, 2002
- Involvement of CYP2J2 and CYP4F12 in the Metabolism of Ebastine in Human Intestinal MicrosomesThe Journal of pharmacology and experimental therapeutics, 2002
- Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects.Int. Journal of Clinical Pharmacology and Therapeutics, 2001
- Triazolam Substrate InhibitionAdvances in Experimental Medicine and Biology, 2001
- Molecular Cloning and Expression of CYP2J2, a Human Cytochrome P450 Arachidonic Acid Epoxygenase Highly Expressed in HeartJournal of Biological Chemistry, 1996